亿帆医药：公司产品被纳入2025年国家医保目录

Core Viewpoint - Yifan Pharmaceutical (002019) announced that some of its wholly-owned or controlled subsidiaries' self-owned or imported general distribution products have been included in the "2025 National Medical Insurance Directory" [1] Group 1: Product Inclusion - The innovative drug Aibegesitin α injection (Yilishu) and the imported general distribution product Dihyaluronic Acid Sodium Injection (Yinikon) have been renewed for inclusion in the directory [1] - The compound Huangdai tablets (Baixuekang) have been adjusted to the regular national medical insurance directory [1] - Other products already included in the national medical insurance directory by the company's subsidiaries did not experience any adjustments [1] Group 2: Clinical Trials - The company's wholly-owned subsidiary has received a clinical trial approval notice for the in-development product N-3C01 injection, allowing it to conduct clinical trials in patients with advanced solid tumors and non-muscle invasive bladder cancer [1]